ONXX: Summary for ONYX Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Tuesday, November 24, 2009, 3:52am EST - Canadian Markets open in 5 hours and 38 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Onyx Pharmaceuticals Inc. (ONXX)

On Nov 23: 28.08 USD 0.00 (0.00%)

MORE ON ONXX

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

ONYX Pharmaceuticals, Inc. (NGM:ONXX) Delayed quote data

Last Trade:	28.08 USD
Trade Time:	Nov 23
Change:	0.00 (0.00%)
Prev Close:	28.08
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	59.00

Day's Range:	N/A - N/A
52wk Range:	21.85 - 37.02
Volume:	0
Avg Vol (3m):	1,310,030
Market Cap:	1.74B
P/E (ttm):	N/A
EPS (ttm):	-0.89
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add ONXX to Portfolio

Download Data

HEADLINES

•	[$$] U.K. Watchdog Says Bayer's Nexavar Is Too Expensive
	at The Wall Street Journal Online (Fri, Nov 20)

•	[$$] Corporate Watch
	at The Wall Street Journal Online (Thu, Nov 19)

•	UK health unit rejects Bayer drug as too expensive
	at MarketWatch (Thu, Nov 19)

•	Onyx wraps up $276M Proteolix buy
	at bizjournals.com (Mon, Nov 16)

•	ONYX PHARMACEUTICALS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements
	EDGAR Online (Mon, Nov 16)

•	Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc.
	PRNewswire (Mon, Nov 16)

•	Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
	PRNewswire (Wed, Nov 11)

•	Healthcare Guru Adds Selected Biotech, Pharma Stakes
	Indie Research (Wed, Nov 11)

•	Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib and ONX 0803 at 51st American Society of Hematology Annual Meeting
	PRNewswire (Tue, Nov 10)

•	Blood Cancer Meeting Abstracts Released: BioBuzz
	at TheStreet.com (Tue, Nov 10)

More Headlines for ONXX...

ANALYST

EPS Est (next year) (Dec-07) :	-0.52
EPS Est (in 2 years) (Dec-08) :	0.86
Avg Rec (current)*:	2.4
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that target the molecular mechanisms implicated in cancer in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•